Moderna Shares Surge 135% in One Day Following Successful Late-Stage Trial of Groundbreaking Cancer Vaccine

Moderna’s stock experienced a dramatic surge of approximately 135%, reaching $148.02 after the promising results from a late-stage trial of its personalized mRNA cancer vaccine, developed in collaboration with Merck. This vaccine demonstrated a significant reduction in the risk of melanoma recurrence and metastasis when paired with Merck’s Keytruda, suggesting a robust and potentially lucrative avenue for both companies. Notably, Interim results confirmed that the treatment, named Intismeran, not only met its primary goal of reducing cancer recurrence but also the secondary objective of preventing tumor spread, marking a crucial milestone as the first successful late-stage trial for an mRNA cancer vaccine.

The positive trial outcomes come at a consequential time for both Moderna and Merck, as investors remain vigilant about the growth trajectories of each company amidst looming challenges. Merck is poised to face patent expirations for Keytruda, while Moderna seeks to diversify its portfolio beyond the COVID-19 vaccine. Analysts, including William Blair’s Myles Minter, indicate that these promising results bolster the companies’ positions for regulatory approval and bode well for future studies involving the vaccine in other cancer types. The anticipated dialogue with regulators is expected to commence shortly, which could further validate the therapy’s market potential.

Industry analysts estimate that the combined therapy could generate substantial revenue, projecting approximately $3 billion in sales from melanoma treatment by 2035. JP Morgan emphasized the critical importance of launching Intismeran for Moderna’s pathway to profitability. The trial, which enrolled over 1,100 high-risk melanoma patients, has revealed no new safety concerns, further enhancing the attractiveness of the treatment. Furthermore, the manufacturing process, which does not rely on the patient’s own cells, could facilitate economies of scale and, ultimately, cost reductions. Pricing decisions for the therapy remain undetermined, as leadership from both companies weighs their next steps in the wake of recent findings.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)